Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
-
Amicus Therapeutics (FOLD): Raising PT to $17.50 - Chardan
-
Amicus Therapeutics (FOLD): Priority Review Voucher Is A $125 Million Call Option - Chardan
-
Chardan Capital Markets Raises Price Target on Amicus Therapeutics (FOLD); Reiterates Buy
-
Pre-Open Stock Movers 04/12: (FOLD) (ARNA) (HLX) Higher; (HZNP) (OZM) (JNPR) Lower (more...)
-
Amicus Therapeutics (FOLD) Could Be Worth More Than $22.50/Share in a Takeout - Chardan Capital
-
Notable Analyst Rating Changes 10/5: (TWTR) (FOLD) (JNPR) Upgraded; (SNI) (LRCX) (FEYE) Downgraded
-
Pre-Open Stock Movers 10/05: (ONCE) (FOLD) (TWTR) Higher; (APP) (FEYE) (VRX) Lower (more...)
-
Chardan Capital Markets Upgrades Amicus Therapeutics (FOLD) to Buy
-
Unusual 11 Mid-Day Movers 9/16: (ITCI) (ADEP) (XNCR) Higher; (NR) (FOLD) (SPCB) LOwer
-
Notable Analyst Rating Changes 9/16: (CST) (YNDX) (ORCL) Upgraded; (HST) (FOLD) (MRK) Downgraded
-
Chardan Capital Markets Downgrades Amicus Therapeutics (FOLD) to Neutral
-
Amicus (FOLD) Worth Up to $50/Sh in a Takeover, Chardan Says; Scioderm Deal Terms Suggest Future Sale
-
Chardan Capital Markets Starts Amicus Therapeutics (FOLD) at Buy